GLP-1 Medications in Young Children — What Parents Should Know About the New Trials and Prescribing Trends

Bottom Line

GLP-1 medications are being prescribed to young children with obesity far more than they were even a few years ago, and clinical trials are now testing them in children as young as 6. But approval and evidence have not kept pace with use: no GLP-1 medication is currently FDA-approved for obesity treatment in children younger than 12, and only semaglutide and liraglutide are approved for ages 12 and older. Prescribing in children 8–11 remains uncommon in absolute terms but has risen sharply and is concentrated in the most clinically severe cases — both reassuring and a reason for careful, individualized decision-making rather than a blanket answer.

What’s Actually Approved Right Now

• Semaglutide (Wegovy): approved for chronic weight management in adolescents ages 12 and older, based on the STEP TEENS trial.
• Liraglutide (Saxenda, and a 2025-approved generic): approved for ages 12–17 with body weight over 60 kg and obesity, and for adults. Not approved, and not established as safe or effective, in children under 12.

Tirzepatide (Zepbound): approved for adults only — there is no pediatric obesity approval. A separate tirzepatide product, Mounjaro, is approved for type 2 diabetes in patients 10 and older, a different indication that should not be confused with weight-loss use.

• Bottom line on age 12: this is the current floor for any FDA-approved GLP-1 obesity treatment. Anything used below that age is, by definition, off-label or investigational.

What the New Pediatric Trial Data Show

The most direct evidence in children under 12 comes from the SCALE Kids trial, published in the New England Journal of Medicine. This placebo-controlled study randomized 82 children ages 6 to under 12 with obesity to liraglutide or placebo for 56 weeks. Children on liraglutide had a mean body-weight change of +1.6% (essentially holding steady while growing), compared with +10.0% in the placebo group — a meaningful difference, since children are still growing and some weight gain is expected. A clinically meaningful BMI reduction of 5% or more occurred in 46% of the liraglutide group versus 9% on placebo. Gastrointestinal side effects were more common with liraglutide (80% vs. 54% of participants), and the trial was not large or long enough to evaluate rare risks or effects on lean body mass and growth.

This trial supports the biological plausibility of GLP-1 treatment in younger children, but a single 56-week study of 82 children is not the same as an approved, well-characterized treatment. A separate completed safety and pharmacokinetics study of tirzepatide in children ages 6–11 has examined dosing in that age group without establishing an approved use. STAT News reported on September 15, 2026 that additional companies are now planning or running obesity-drug trials in children as young as 6 — meaning more data, but also more years before any of it could become an approved treatment.

What the Prescribing Data Show Today

A study published September 4, 2026 in Pediatrics used electronic health records covering more than 3.5 million children ages 8 to 11 with obesity (and without diabetes) to track GLP-1 prescribing from 2019 through mid-2026. Two figures matter and answer different questions. The annual prescribing rate — the share of children in that age group prescribed a GLP-1 medication during a given year — rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase. Looked at cumulatively over the full study period, 20,282 children ages 8–11 (0.6% of the total cohort) received at least one GLP-1 prescription, compared with 0.9% of adolescents ages 12–17 in the same health system data. Put plainly: use remains uncommon in absolute numbers, but the rate of new prescribing has grown extremely quickly.

• Prescribing was concentrated in higher-severity cases: 93.7% of the 8–11 group who received a GLP-1 had severe obesity, 65.2% had at least one weight-related comorbidity, and roughly a quarter had prediabetes.
• Prescribing was not evenly distributed by income: children in higher-income communities were prescribed GLP-1 medications at a 55% higher rate than those in lower-income communities — an access and equity question worth watching.
• Since none of these medications are approved for children under 12, virtually all of this prescribing in the 8–11 age group is necessarily off-label.

Limitations

• Long-term effects on growth, bone development, puberty, and lean body mass have not been established in large, long-duration pediatric trials.
• What happens when a child stops treatment — whether weight regain patterns mirror those seen in adults — is not yet well characterized in this age group.
• Optimal duration of treatment in a still-growing child is an open clinical question, not a solved one.
• Psychological and behavioral effects of early pharmacologic treatment for a chronic condition are an active area of research, not a settled finding.

BeLite Clinical Perspective

BeLite is a physician-supervised weight management practice for adults, and we do not market or provide services directly to young children. For families weighing pharmacologic treatment for a child under 12, our honest guidance is the same standard that applies to any off-label, still-evolving area of medicine: this decision belongs with a pediatrician or pediatric obesity specialist who can weigh your child’s specific health picture, monitor growth and development over time, and stay current with a fast-moving evidence base. For older teens and adults in the household considering GLP-1 treatment for themselves, the approved-medication evidence is far more mature — our guides to what to expect after stopping treatment and protecting muscle during weight loss cover that ground in detail.

FAQs

Q: Is Wegovy or Zepbound approved for young children?

A: No. Semaglutide (Wegovy) is approved starting at age 12. Zepbound (tirzepatide) has no pediatric obesity approval at any age. No GLP-1 medication is approved for obesity treatment in children under 12.

Q: My child’s doctor is considering a GLP-1 for my 9-year-old — is that appropriate?

A: It would be off-label use. Some pediatric obesity specialists consider it in children with severe obesity and significant health complications, under close supervision, but this is an individualized decision that belongs with a pediatrician or pediatric obesity specialist familiar with your child’s full health picture — not a general recommendation.

Q: How common is this really?

A: Still uncommon in absolute terms — roughly 0.6% of children 8–11 with obesity had ever received a GLP-1 prescription through mid-2026 — but the annual rate of new prescribing has risen 310-fold since 2019, concentrated in the most severe cases.

Q: Are trials testing these drugs in even younger children?

A: Yes. As of September 2026, companies are running or planning trials in children as young as 6, following the published SCALE Kids trial in children ages 6 to under 12.

References

1. Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesity — a randomized trial (SCALE Kids). N Engl J Med. 2024. PMID 39258838.
2. Orandi BJ, Patel SS, Messito MJ, et al. Trends in GLP-1 receptor agonist prescriptions for children ages 8 to 11 with obesity: 2019–2026. Pediatrics. 2026;e2026077048.
3. STAT News (The Readout). Obesity drugmakers are testing them in children as young as 6. September 15, 2026.
4. BeLite Medical Center. Zepbound.
5. BeLite Medical Center. Our Medications.
6. BeLite Medical Center. What Happens After Stopping Wegovy or Zepbound?
7. BeLite Medical Center. GLP-1 Muscle Loss: How Much Lean Mass Is Lost?